JP2015533163A - 多発性硬化症における視床損傷を低減するためのラキニモド - Google Patents

多発性硬化症における視床損傷を低減するためのラキニモド Download PDF

Info

Publication number
JP2015533163A
JP2015533163A JP2015536853A JP2015536853A JP2015533163A JP 2015533163 A JP2015533163 A JP 2015533163A JP 2015536853 A JP2015536853 A JP 2015536853A JP 2015536853 A JP2015536853 A JP 2015536853A JP 2015533163 A JP2015533163 A JP 2015533163A
Authority
JP
Japan
Prior art keywords
laquinimod
subject
thalamic
administered
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015536853A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015533163A5 (enExample
Inventor
フィリッピ、マッシモ
コミ、ジアンカルロ
ロッカ、マリア、アシュンタ
Original Assignee
テバ ファーマシューティカル インダストリーズ リミティド
テバ ファーマシューティカル インダストリーズ リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by テバ ファーマシューティカル インダストリーズ リミティド, テバ ファーマシューティカル インダストリーズ リミティド filed Critical テバ ファーマシューティカル インダストリーズ リミティド
Publication of JP2015533163A publication Critical patent/JP2015533163A/ja
Publication of JP2015533163A5 publication Critical patent/JP2015533163A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
JP2015536853A 2012-10-12 2013-10-09 多発性硬化症における視床損傷を低減するためのラキニモド Pending JP2015533163A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261713256P 2012-10-12 2012-10-12
US61/713,256 2012-10-12
PCT/US2013/064061 WO2014058979A2 (en) 2012-10-12 2013-10-09 Laquinimod for reducing thalamic damage in multiple sclerosis

Publications (2)

Publication Number Publication Date
JP2015533163A true JP2015533163A (ja) 2015-11-19
JP2015533163A5 JP2015533163A5 (enExample) 2016-11-24

Family

ID=50475887

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015536853A Pending JP2015533163A (ja) 2012-10-12 2013-10-09 多発性硬化症における視床損傷を低減するためのラキニモド

Country Status (18)

Country Link
US (2) US20140107154A1 (enExample)
EP (1) EP2961406A4 (enExample)
JP (1) JP2015533163A (enExample)
KR (1) KR20150080509A (enExample)
CN (1) CN105263325A (enExample)
AR (1) AR092993A1 (enExample)
AU (2) AU2013329348A1 (enExample)
BR (1) BR112015007782A2 (enExample)
CA (1) CA2884272A1 (enExample)
CL (2) CL2015000732A1 (enExample)
EA (1) EA201590726A1 (enExample)
HK (1) HK1218865A1 (enExample)
IL (1) IL237745A0 (enExample)
MX (1) MX2015004564A (enExample)
PE (1) PE20151435A1 (enExample)
SG (1) SG11201501874TA (enExample)
TW (1) TW201420101A (enExample)
WO (1) WO2014058979A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013116657A1 (en) 2012-02-03 2013-08-08 Teva Pharmaceutical Industries Ltd. USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY
MX2014009889A (es) 2012-02-16 2014-11-13 Teva Pharma N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinoli ncarboxamida, preparacion y usos de los mismos.
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
KR20150119227A (ko) * 2013-02-15 2015-10-23 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드에 의한 다발성 경화증의 진행형 형태의 치료
BR112016014507A2 (pt) * 2013-12-20 2018-05-22 Teva Pharma uso de laquinimod para retardar progressão da doença de huntington
HK1231413A1 (zh) 2014-04-29 2017-12-22 Teva Pharmaceutical Industries Ltd. 用於治疗具有高残疾状况的复发-缓解型多发性硬化症(rrms)的患者的拉喹莫德
CN107683135A (zh) 2015-03-09 2018-02-09 因特克林医疗有限公司 用于治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法
WO2017048457A1 (en) * 2015-09-18 2017-03-23 Teva Pharmaceuticals Industries Ltd. Combination of laquinimod and pridopidine to treat multiple sclerosis
BR112019004791A2 (pt) * 2016-09-13 2019-06-04 Intekrin Therapeutics Inc tratamento de esclerose múltipla com chs-131
AU2018249822A1 (en) 2017-04-03 2019-10-31 Coherus Biosciences Inc. PPArgamma agonist for treatment of progressive supranuclear palsy
CN113397757A (zh) * 2021-06-07 2021-09-17 温州医科大学 用于测试拉喹莫德在治疗缺血性脑卒中的作用的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006204699B2 (en) * 2005-01-13 2012-04-26 Sirtris Pharmaceuticals, Inc. Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
JP2009543823A (ja) * 2006-07-17 2009-12-10 ノバルティス アクチエンゲゼルシャフト 免疫調節剤として使用するための胆汁酸アミドのスルホニルアミノカルボニル誘導体
AR073295A1 (es) * 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
NZ597378A (en) * 2009-06-19 2014-08-29 Teva Pharma Treatment of multiple sclerosis with laquinimod
WO2011019375A1 (en) * 2009-08-10 2011-02-17 Teva Pharmaceutical Industries Ltd. Treatment of bdnf-related disorders using laquinimod
WO2011086470A1 (en) * 2010-01-13 2011-07-21 Ramot At Tel-Aviv University Ltd Treatment of multiple sclerosis
PE20140872A1 (es) * 2010-12-07 2014-08-09 Teva Pharma Uso de laquinimod para reducir la fatiga, mejorar el estado funcional y mejorar la calidad de vida en pacientes con esclerosis multiple
WO2012131539A1 (en) * 2011-03-31 2012-10-04 Pfizer Inc. Novel bicyclic pyridinones
SG11201401330YA (en) * 2011-10-12 2014-05-29 Teva Pharma Treatment of multiple sclerosis with combination of laquinimod and fingolimod
TW201804997A (zh) * 2012-05-02 2018-02-16 以色列商泰瓦藥品工業有限公司 高劑量拉喹莫德(laquinimod)於治療多發性硬化症之用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ARCH NEUROL, vol. 61(2), JPN6017024652, 2004, pages 226 - 230, ISSN: 0003931146 *
N ENGL J MED, vol. 366(11), JPN6017024651, 15 March 2012 (2012-03-15), pages 1000 - 1009, ISSN: 0003931145 *

Also Published As

Publication number Publication date
SG11201501874TA (en) 2015-05-28
CA2884272A1 (en) 2014-04-17
WO2014058979A3 (en) 2015-08-20
CN105263325A8 (zh) 2017-07-14
KR20150080509A (ko) 2015-07-09
CL2015000732A1 (es) 2015-08-07
MX2015004564A (es) 2015-07-21
US20160296511A1 (en) 2016-10-13
HK1218865A1 (zh) 2017-03-17
TW201420101A (zh) 2014-06-01
IL237745A0 (en) 2015-05-31
AU2017203896A1 (en) 2017-06-29
US20140107154A1 (en) 2014-04-17
WO2014058979A8 (en) 2015-04-16
CN105263325A (zh) 2016-01-20
PE20151435A1 (es) 2015-10-15
AR092993A1 (es) 2015-05-13
CL2016002873A1 (es) 2017-04-17
EP2961406A4 (en) 2017-01-04
EA201590726A1 (ru) 2015-10-30
EP2961406A2 (en) 2016-01-06
BR112015007782A2 (pt) 2017-07-04
AU2013329348A1 (en) 2015-05-28
WO2014058979A2 (en) 2014-04-17

Similar Documents

Publication Publication Date Title
CN103260624B (zh) 拉喹莫德用于在多发性硬化症患者中减少疲劳、改善功能状态和改善生活品质的用途
JP2017222691A (ja) 多発性硬化症を治療するための高投与量ラキニモドの使用
ES2548999T3 (es) Tratamiento de la esclerosis múltiple con laquinimod
US20160296511A1 (en) Laquinimod for reducing thalamic damage in multiple sclerosis
JP2017061482A (ja) ラキニモドおよびインターフェロンβを組み合わせた多発性硬化症の治療
JP2016510343A (ja) ラキニモドを用いる多発性硬化症の治療
JP2017514824A (ja) 能力障害度が高い再発寛解型多発性硬化症（ｒｒｍｓ）患者の処置のためのラキニモド
TW201408300A (zh) 以拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）及氨吡啶（ｆａｍｐｒｉｄｉｎｅ）之組合治療多發性硬化症
HK1224555A1 (en) Use of high dose laquinimod for treating multiple sclerosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161006

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161006

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170704

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170926

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181204